VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VivoSim Labs (VIVS) signed a seven-figure testing agreement with a top-10 global pharmaceutical company. Work is underway on NAMkind liver and intestinal toxicology testing. VivoSim expects the agreement to push fiscal 2027 revenue growth above its 500%+ guidance, with contract revenue expected to be recognized in fiscal Q3 and Q4, ending December 31 and March 31, respectively.
Both toxicology businesses grew in the quarter ended September 30, 2026, with orders from large drugmakers and smaller biotech companies. VivoSim anticipates the customer will make NAMkind part of its routine preclinical testing after the program ends.
VivoSim also added testing to assess drug effects in liver and intestinal disease models and entered a collaboration with Chemveda Life Sciences to test compounds in human tissue models. The first programs are expected to begin this quarter.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Fiscal 2027 revenue growth is expected to exceed VivoSim’s 500%+ guidance with the agreement
- Major pointSeven-figure testing agreement with a top-10 global drugmaker covers liver and intestinal toxicology work already underway
- Moderate pointLiver toxicology business grew in the quarter ended September 30, 2026
- Moderate pointIntestinal toxicology business grew in the quarter ended September 30, 2026
- Minor point. Forward-looking: it has not happened yet and may not happen.Routine preclinical testing with NAMkind is anticipated by VivoSim after the customer’s current program ends
Negative
- None.
Key Figures
- Agreement value
- Seven-figure
- NAMkind testing services agreement with a top-10 global pharmaceutical company
- Fiscal 2027 revenue growth guidance
- 500%+ growth
- Company expects fiscal 2027 revenue to exceed this guidance
- Revenue recognition period
- Fiscal Q3 and Q4
- Expected recognition; periods end Dec. 31 and March 31, respectively
- Compounds in clinical dataset
- 92 small-molecule compounds
- Dataset used to assess the NAMkind Liver model
- Prediction accuracy
- 91%
- NAMkind Liver model prediction of drug-induced liver injury
- Sensitivity
- 90%
- NAMkind Liver model
- Specificity
- 95%
- NAMkind Liver model
- True liver toxicants detected
- 50% to 65%
- Typical detection by animal models and traditional methods
Key Terms
new approach methodologies technical
drug-induced liver injury medical
specificity technical
pharmacodynamic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Liver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind™ testing part of its regular flow of ongoing preclinical work
SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety and efficacy testing, today announced a seven-figure agreement with a top-10 global pharmaceutical company (the “Customer”) for NAMkind™ testing services. With this agreement, the Company expects fiscal 2027 revenue to exceed the guidance of
- The agreement covers NAMkind™ liver and intestinal toxicology testing, with work already underway. Revenue under the agreement is expected to be recognized in VivoSim’s fiscal Q3 and Q4, ending Dec. 31 and March 31, respectively.
- After this program, VivoSim anticipates that NAMkind™ testing will become part of the Customer's regular flow of ongoing preclinical work.
- The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 12, shows growth in both its liver toxicology and intestinal toxicology businesses.
- Growth came from both large pharma and smaller customers. Other current and future customers are also expected to move toward full integration of NAMkind™ testing into their workflows
How a Large Customer Adopts a New Test
A large pharmaceutical company (>
“In July we told shareholders revenue would grow more than
Since the Quarter Closed
On October 21, VivoSim added efficacy testing on disease models built from the liver and intestinal cells of patient donors, with pharmacodynamic and target biomarker profiling. On November 3, it entered a collaboration with Chemveda Life Sciences, which makes AI-designed compounds that VivoSim will then test in its human tissue models, with first programs expected to begin this quarter. This week, the Company's scientists are presenting new data demonstrating the practical impact on clinical derisking for clients of its multiparametric approach at the American College of Toxicology 47th Annual Meeting in San Antonio, Texas. The Company’s leadership is also meeting with current and prospective partners at the conference.
What Customers Are Buying
NAMkind™ liver and intestine models are built from primary human cells and dosed repeatedly over weeks. Across a clinical dataset of 92 small-molecule compounds, the NAMkind™ Liver model predicted drug-induced liver injury with
“Both toxicology service lines grew in the September quarter, with orders from large pharmaceutical companies and from smaller biotechs,” said Tony Lialin, Chief Commercial Officer of VivoSim Labs. “A large customer comes in through an evaluation, then a paid program, then its standing workflow. This Customer is at the second step, and we have others at the first.”
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company's expectation that fiscal 2027 revenue will exceed its guidance of
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.